FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
|Peer-Reviewed|December 23, 2020
- January 2021
- Volume 27
- Issue 1
Supplemental Material: Chemotherapy-Induced Peripheral Neuropathy in Metastatic Breast Cancer Patients Initiating Intravenous Paclitaxel/nab-Paclitaxel
Supplemental materials for article examining the incidence and impact of chemotherapy induced peripheral neuropathy on clinical and economic outcomes in women with metastatic breast cancer initiating intravenous paclitaxel/nab-paclitaxel.
Advertisement
Articles in this issue
over 5 years ago
ASH 2020: Clinical Updatesover 5 years ago
ASH 2020: COVID-19 and Hematologyover 5 years ago
ASH 2020: CAR T-Cell Therapy Updatesover 5 years ago
ASH 2020: The Next Waveover 5 years ago
2020 SABCS: Topics in Precision OncologyAdvertisement
Related to this article
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5